Report Description Table of Contents Eosinophilic Granulomatosis with Polyangiitis Treatment Market: Biologics Redefine Steroid-Sparing Disease Control The Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market was valued at USD 415 million in 2025 and is projected to reach USD 810 million by 2032, expanding at a CAGR of 9.85% during 2026–2032, according to Strategic Market Research. Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and complex autoimmune inflammatory disorder driven by abnormal eosinophil activation and inflammation of small and medium-sized blood vessels. Although EGPA affects a small patient population, its clinical impact is significant. Global epidemiological studies estimate an incidence of 1.22 new cases per million people annually, while prevalence estimates vary widely from 2.0 to 38.0 cases per million people, with systemic analyses reporting an average prevalence of approximately 34.44 cases per million. The disease burden remains considerable, with 17%–42% of patients requiring hospitalization, 25%–42% requiring emergency care, and mortality estimated at 10.63 deaths per 1,000 person-years, reinforcing the need for advanced targeted therapies and improved long-term disease management. Mepolizumab marked a major advancement in EGPA treatment by becoming the first FDA-approved biologic therapy specifically indicated for eosinophilic granulomatosis with polyangiitis, introducing a targeted, steroid-sparing approach for patients requiring long-term disease control. The therapeutic landscape is further evolving with the development of additional biologics, including benralizumab, an anti–IL-5 receptor therapy that has shown encouraging clinical outcomes. In comparative studies, benralizumab achieved remission at weeks 36 and 48 in 59% of patients, compared with 56% receiving mepolizumab, highlighting its potential as an alternative targeted treatment option for improving disease management and reducing dependence on corticosteroids Overall, the EGPA treatment market is moving toward precision-based, steroid-sparing approaches that aim to improve remission durability, reduce relapse burden, and minimize long-term complications associated with conventional therapy. Key Report Takeaways—Biologics Shift EGPA Treatment Beyond Steroid Dependence By Drug Class Biologic Therapies lead with a 40% share, generating USD 166.0 million in 2025, and are projected to record the fastest CAGR of 14.7% during 2026–2032. Steroids/Glucocorticoids account for a 34% share, equivalent to USD 141.1 million, and are expected to expand at a 5.2% CAGR. Immunosuppressants hold a 22% share, representing USD 91.3 million, with a projected CAGR of 7.2%. Immune Globulins and Other Adjunctive Therapies represent a 4% share, generating USD 16.6 million, and are forecast to grow at a 6.0% CAGR. By Route of Administration Subcutaneous/Intramuscular therapies lead with a 41% share and USD 170.2 million in revenue, expanding at the fastest CAGR of 14.0%. Oral therapies account for 35%, generating USD 145.3 million, with a projected CAGR of 5.8%. Intravenous therapies hold a 24% share, equivalent to USD 99.6 million, and are expected to grow at an 8.1% CAGR. By Distribution Channel Specialty Pharmacies lead with a 44% share, generating USD 182.6 million, and are projected to expand at a 13.5% CAGR. Hospital Pharmacies represent 38% of the market, equivalent to USD 157.7 million, with a 7.2% CAGR. Retail and Online Pharmacies account for 18%, generating USD 74.7 million, and are forecast to grow at a 5.2% CAGR. By End User Hospitals and Clinics dominate with a 68% share, representing USD 282.2 million, and are projected to grow at an 8.0% CAGR. Home Healthcare holds a 32% share, generating USD 132.8 million, and is expected to record the fastest CAGR of 13.7%. By Geography North America leads with a 41% share and USD 170.2 million, expanding at a 10.0% CAGR. Europe accounts for 34%, generating USD 141.1 million, with a projected CAGR of 9.1%. Asia-Pacific holds an 18% share, equivalent to USD 74.7 million, and is the fastest-growing region at a 12.4% CAGR. Latin America, the Middle East and Africa collectively represent 7%, generating USD 29.1 million, with a forecast CAGR of 7.6%. Segment Leadership—Targeted Biologics Reshape Revenue Concentration By Drug Class Leading Subsegment: Biologic Therapies Biologic therapies lead the drug-class segment with an estimated 40% market share and USD 166.0 million in 2025 revenue. The segment includes anti-IL-5 and anti-IL-5 receptor therapies such as mepolizumab and benralizumab. Their high treatment value and ability to reduce corticosteroid dependence allow biologics to generate greater revenue than widely used but inexpensive glucocorticoids. In the MANDARA trial, remission at weeks 36 and 48 was achieved by 59% of benralizumab-treated patients and 56% of mepolizumab-treated patients. Fastest-Growing Subsegment: Biologic Therapies Biologics are projected to expand at the fastest CAGR of 14.7% during 2026–2032. Growth will come from increased use in relapsing, refractory, and steroid-dependent EGPA, supported by longer treatment duration and wider reimbursement. The segment is expected to gain revenue share from conventional immunosuppressants and long-term corticosteroid regimens. By Route of Administration Leading Subsegment: Subcutaneous/Intramuscular The subcutaneous/intramuscular category accounts for an estimated 41% share, equivalent to USD 170.2 million in 2025 revenue. Subcutaneous administration dominates this category because mepolizumab and benralizumab are delivered through prefilled syringes or autoinjectors. The route supports recurring maintenance treatment without repeated intravenous infusion visits. Fastest-Growing Subsegment: Subcutaneous/Intramuscular This category is forecast to record the fastest CAGR of 14.0%. Expansion is supported by rising biologic use, convenient maintenance dosing, and greater potential for supervised self-administration. Growth will gradually shift treatment revenue away from oral corticosteroids, although oral therapies will remain widely used. By Distribution Channel Leading Subsegment: Specialty Pharmacies Specialty pharmacies lead with an estimated 44% share and USD 182.6 million in 2025 revenue. These pharmacies manage high-cost biologics, prior authorization, cold-chain handling, refill coordination, and patient-support programs, making them central to long-term EGPA biologic treatment. Fastest-Growing Subsegment: Specialty Pharmacies Specialty pharmacies are projected to expand at a 13.5% CAGR. Growth reflects the rising proportion of market revenue generated by mepolizumab, benralizumab, and future targeted therapies rather than inexpensive oral medicines supplied through retail pharmacies. By End User Leading Subsegment: Hospitals and Clinics Hospitals and clinics dominate with a 68% share, representing USD 282.2 million in 2025 revenue. These facilities handle diagnosis, organ-damage assessment, severe-flare treatment, intravenous cyclophosphamide or rituximab administration, and multidisciplinary follow-up involving rheumatologists, pulmonologists, cardiologists, and neurologists. Fastest-Growing Subsegment: Home Healthcare Home healthcare is projected to grow at the fastest CAGR of 13.7%, from a 32% share and USD 132.8 million in 2025. Prefilled biologic devices and stable maintenance regimens are increasing the proportion of treatment managed outside hospitals. By Geography Leading Subsegment: North America North America leads with a 41% market share, equivalent to USD 170.2 million in 2025 revenue. Its position reflects early biologic approvals, established orphan-drug reimbursement, specialist treatment centers, and high-value therapy adoption. Fastest-Growing Subsegment: Asia-Pacific Asia-Pacific holds an estimated 18% share, generating USD 74.7 million in 2025, and is projected to record the fastest CAGR of 12.4%. Growth will come from improving specialist access, better recognition of eosinophilic disorders, expanding biologic availability, and gradual reimbursement development. Treatment Pathways—Where EGPA Therapy Generates Recurring Demand Remission Induction Remission induction represents the initial treatment application for patients with newly diagnosed or actively relapsing EGPA. High-dose oral prednisone or intravenous methylprednisolone is used to control eosinophilic inflammation quickly. Patients with severe cardiac, renal, neurological, gastrointestinal, or pulmonary involvement may also receive cyclophosphamide or rituximab. This application sustains demand for corticosteroids, intravenous immunosuppressants, hospital pharmacies, and specialist-led inpatient care. Remission Maintenance Maintenance treatment prevents renewed disease activity after initial symptoms and organ inflammation have been controlled. Depending on disease severity and previous response, patients may receive low-dose corticosteroids, azathioprine, methotrexate, mycophenolate mofetil, mepolizumab, or benralizumab. Maintenance represents an important recurring-revenue application because EGPA is a chronic condition requiring prolonged monitoring and medication. The risk of relapse means that treatment may continue for several years rather than ending after initial remission. Relapsing or Refractory EGPA Targeted biologics have become particularly important for patients whose disease returns during corticosteroid tapering or remains uncontrolled with conventional immunosuppressants. In the 136-patient MIRRA trial, 28% of mepolizumab-treated patients achieved at least 24 weeks of accrued remission, compared with 3% receiving placebo. Mepolizumab also reduced the annualized relapse rate from 2.27 to 1.14. This application is supporting rapid revenue growth for anti-IL-5 therapies. Severe and Organ-Threatening EGPA Severe EGPA can cause myocarditis, cardiomyopathy, glomerulonephritis, mononeuritis multiplex, gastrointestinal ischemia, or pulmonary hemorrhage. These patients generally require high-dose glucocorticoids combined with cyclophosphamide or rituximab. Published evidence indicates that 17%–42% of EGPA patients require hospitalization, illustrating the clinical and economic importance of acute organ-protection therapy. Hospital-based treatment remains essential because these cases require intravenous medication, organ assessment, and multidisciplinary monitoring. Corticosteroid-Sparing Treatment Reducing long-term corticosteroid exposure is one of the fastest-expanding EGPA treatment applications. In the MIRRA trial, 44% of mepolizumab-treated patients reduced their average corticosteroid dose to 4 mg per day or less, compared with 7% receiving placebo. The MANDARA trial further showed that 41% of benralizumab-treated patients completely discontinued oral corticosteroids, versus 26% receiving mepolizumab. These outcomes support wider biologic adoption among steroid-dependent patients. Eosinophilic Respiratory Manifestation Control Asthma, chronic sinus disease, nasal polyps, and eosinophilic pulmonary inflammation affect a large proportion of EGPA patients and may persist even when systemic vasculitis is controlled. Anti-IL-5 and IL-5 receptor therapies address these recurring respiratory manifestations by reducing eosinophil activity. Their ability to manage both vasculitic and respiratory components strengthens long-term treatment retention and expands biologic use across pulmonology, allergy, and rheumatology settings. Competitive Landscape—Two Approved Biologics Lead While Oral Pipeline Competition Emerges 1. GSK plc—Established Leader with the First EGPA-Specific Biologic GSK holds a leading position through Nucala (mepolizumab), the first targeted biologic approved by the U.S. FDA specifically for adult EGPA in 2017. Nucala targets interleukin-5 and is administered as three 100-mg subcutaneous injections every four weeks. Its first-mover status, long clinical history, and ability to address both EGPA and associated eosinophilic respiratory disease support its strong treatment position. In the 136-patient MIRRA trial, 28% of mepolizumab-treated patients achieved at least 24 weeks of accrued remission, compared with 3% receiving placebo. Mepolizumab reduced the annualized relapse rate to 1.14, versus 2.27 with placebo. Furthermore, 44% of treated patients reduced their average corticosteroid dose to 4 mg or less per day, compared with 7% in the placebo group. These results established the clinical basis for targeted biologic treatment in EGPA. 2. AstraZeneca plc—Strongest Direct Challenger in Targeted Biologics AstraZeneca became GSK’s primary direct competitor after Fasenra (benralizumab) received U.S. approval for adult EGPA in September 2024. Fasenra targets the IL-5 receptor alpha and rapidly depletes eosinophils. Its single 30-mg subcutaneous injection every four weeks provides a lower injection burden than the three injections required for the approved EGPA dose of mepolizumab. The 140-patient MANDARA Phase III trial reported remission at weeks 36 and 48 in 59% of benralizumab-treated patients, compared with 56% receiving mepolizumab, confirming noninferiority. Approximately 41% of patients receiving benralizumab completely discontinued oral corticosteroids, versus 26% receiving mepolizumab. These results position AstraZeneca strongly in steroid-sparing maintenance treatment. 3. NS Pharma/Nippon Shinyaku—Leading Emerging Pipeline Participant NS Pharma represents an important emerging competitor through NS-229, an investigational oral selective JAK1 inhibitor. Unlike injectable anti-IL-5 biologics, NS-229 is designed to suppress several inflammatory pathways through an oral treatment format, potentially widening future treatment choice. NS-229 is currently listed in Phase II development for EGPA and received FDA Fast Track designation in July 2025. Clinical efficacy data have not yet established its competitive position, but regulatory recognition and oral administration make it one of the market’s most relevant pipeline candidates. Other Market Participants Roche/Genentech: Supplies Rituxan/MabThera (rituximab), an off-label option for severe or ANCA-positive EGPA; a 105-patient trial recorded remission in 63.5% with rituximab versus 60.4% with conventional therapy, without demonstrating superiority. Novartis: Participates through Xolair (omalizumab), which may be used off-label in selected asthma-dominant EGPA cases but lacks an EGPA-specific regulatory approval. Sanofi and Regeneron: Maintain strong expertise in type-2 inflammatory diseases through Dupixent, although dupilumab is not approved as an EGPA treatment. Pfizer: Supports conventional treatment through corticosteroid products, including methylprednisolone, used for rapid inflammation control and severe disease flares. Sandoz: Supplies lower-cost generic corticosteroids and immunosuppressants used in EGPA induction and maintenance regimens. Teva Pharmaceutical: Participates primarily through generic oral and injectable medicines used for inflammation control and long-term immunosuppression. Viatris: Provides established generic medicines used across corticosteroid and conventional immunosuppressive treatment pathways. Analyst Commentary—Sustained Remission and Steroid Reduction Will Define Leadership The EGPA treatment market is moving toward long-term disease control with lower corticosteroid exposure. Future competition will depend less on short-term suppression of inflammation and more on sustained remission, relapse prevention, convenient administration, and measurable steroid reduction. Anti-IL-5 and IL-5 receptor biologics currently hold the strongest position, but oral targeted therapies could reshape treatment selection if they demonstrate comparable efficacy with simpler administration. Companies that combine clear clinical differentiation with broader reimbursement, specialist education, biomarker-based patient selection, and reliable access through specialty pharmacies will be best positioned to capture the market’s shift toward personalized maintenance treatment. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 415 Million Revenue Forecast in 2032 USD 810 Million Overall Growth Rate CAGR of 9.85% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Drug Class, By Route of Administration, By Distribution Channel, By End User, By Geography By Drug Class Biologic Therapies, Steroids/Glucocorticoids, Immunosuppressants, Immune Globulins and Other Adjunctive Therapies By Route of Administration Subcutaneous/Intramuscular, Oral, Intravenous By Distribution Channel Specialty Pharmacies, Hospital Pharmacies, Retail and Online Pharmacies By End User Hospitals and Clinics, Home Healthcare By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Precision-based, steroid-sparing approaches that aim to improve remission durability, reduce relapse burden, and minimize long-term complications associated with conventional therapy Customization Option Available upon request Frequently Asked Question About This Report Q1. What is moving treatment spending toward faster growth in this market? A1. Demand is shifting from low-cost corticosteroids toward higher-value biologics that support sustained remission and lower steroid exposure. Recurring maintenance therapy also creates long-term revenue. The market is projected to increase from USD 415 million in 2025 to USD 810 million by 2032. Q2. Why are biologics capturing a larger share of industry revenue? A2. Mepolizumab and benralizumab target the IL-5 pathway and can reduce relapses as well as corticosteroid dependence. Biologics held a 40% share worth USD 166.0 million in 2025. The segment is projected to grow at the fastest CAGR of 14.7%. Q3. What makes subcutaneous administration important to this market? A3. Subcutaneous biologics can be delivered through prefilled syringes or autoinjectors without repeated intravenous infusion visits. This route held a leading 41% share and generated USD 170.2 million in 2025. It is projected to grow at a 14.0% CAGR through 2032. Q4. How are specialty pharmacies supporting the industry’s move toward targeted care? A4. Specialty pharmacies manage prior authorization, cold-chain storage, refill coordination, and patient-support programs for high-cost biologics. They led the distribution segment with a 44% share and USD 182.6 million in 2025 revenue. Q5. What is accelerating home-based treatment within this market? A5. Prefilled biologic devices and stable maintenance regimens allow eligible patients to receive more treatment outside hospitals. Home healthcare held a 32% share worth USD 132.8 million in 2025 and is projected to record the fastest end-user CAGR of 13.7%. Q6. Where is the industry’s next regional growth wave forming? A6. North America remains the revenue leader with a 41% share due to early biologic approvals and established reimbursement. Asia-Pacific is projected to grow fastest at a 12.4% CAGR as specialist access, disease recognition, biologic availability, and reimbursement improve. Sources: Epidemiology and Disease Burden Jakes et al. — Burden of illness associated with eosinophilic granulomatosis with polyangiitis: systematic review and meta-analysis Supports the pooled incidence estimate of 1.22 cases per million person-years, hospitalization rates of 17%–42%, and emergency-care utilization of 25%–42%. Dolin et al. — Epidemiology, mortality, healthcare utilization and costs in EGPA Supports the pooled mortality estimate of approximately 10.63 deaths per 1,000 person-years. Incidence, Prevalence, and Mortality of EGPA in Korea: Nationwide Population-Based Study Provides population-level evidence on EGPA incidence, prevalence, survival, and disease burden. Treatment Guidelines and Clinical Management 2021 American College of Rheumatology/Vasculitis Foundation Guideline for ANCA-Associated Vasculitis Supports recommendations involving glucocorticoids, cyclophosphamide, rituximab, mepolizumab, remission induction, and maintenance treatment. Evidence-Based Guideline for the Diagnosis and Management of EGPA Covers organ-threatening EGPA, biologic therapy, corticosteroid reduction, multidisciplinary management, and long-term monitoring. Vasculitis Foundation — Eosinophilic Granulomatosis with Polyangiitis Provides an accessible overview of symptoms, organ involvement, diagnosis, and established treatment approaches. Mepolizumab and the MIRRA Trial Wechsler et al. — Mepolizumab or Placebo for EGPA, New England Journal of Medicine Supports the 136-patient MIRRA trial findings: At least 24 weeks of accrued remission: 28% versus 3% Annualized relapse rate: 1.14 versus 2.27 Corticosteroid dose of 4 mg/day or less: 44% versus 7% GSK — U.S. Approval of Nucala for Adult EGPA Supports Nucala’s 2017 FDA approval as the first targeted biologic specifically approved for EGPA. European Medicines Agency — Nucala Provides regulatory indications, administration information, clinical evidence, and safety information for mepolizumab. Benralizumab and the MANDARA Trial Wechsler et al. — Benralizumab versus Mepolizumab for EGPA, New England Journal of Medicine Supports the 140-patient MANDARA findings: Remission at weeks 36 and 48: 59% with benralizumab versus 56% with mepolizumab Complete oral-glucocorticoid discontinuation: 41% versus 26% Benralizumab demonstrated noninferiority to mepolizumab ClinicalTrials.gov — MANDARA Trial, NCT04157348 Provides the official study design, eligibility criteria, endpoints, interventions, and trial status. AstraZeneca — Fasenra Approved in the United States for EGPA Supports the September 2024 FDA approval, 30-mg subcutaneous dosing, and MANDARA-based efficacy findings. DailyMed — Fasenra Prescribing Information Official prescribing information covering the EGPA indication, dosage, prefilled delivery devices, administration, warnings, and adverse reactions. Emerging Pipeline NS Pharma — NS-229 Selective JAK1 Inhibitor Describes NS-229’s mechanism and Phase II development program for EGPA. ClinicalTrials.gov — Phase II Study of NS-229, NCT06046222 Provides the official Phase II study design, treatment arms, outcome measures, and participating regions. NS Pharma — Corporate News and Regulatory Updates Contains the official Fast Track designation announcement for NS-229. Table of Contents - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Drug Class, Route of Administration, Distribution Channel, End User, and Geography Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Drug Class, Route of Administration, Distribution Channel, End User, and Geography Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Drug Class, Route of Administration, Distribution Channel, and End User Investment Opportunities in the Eosinophilic Granulomatosis with Polyangiitis Treatment Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Biologic Therapies, Subcutaneous/Intramuscular Administration, Specialty Pharmacies, Home Healthcare, and Asia-Pacific Market Expansion Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Targeted Biologics, Steroid-Sparing Treatment, Sustained Remission, Relapse Prevention, and Long-Term Disease Management in EGPA Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory Approvals, Reimbursement, Orphan-Drug Access, and Treatment Guidelines Role of Biologic Therapies, Steroid-Sparing Strategies, Specialty Pharmacy Services, and Home-Based Treatment in Market Expansion Importance of Sustained Remission, Relapse Prevention, Convenience of Administration, and Reduced Corticosteroid Exposure in EGPA Treatment Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Class: Biologic Therapies Steroids/Glucocorticoids Immunosuppressants Immune Globulins and Other Adjunctive Therapies Market Analysis by Route of Administration: Subcutaneous/Intramuscular Oral Intravenous Market Analysis by Distribution Channel: Specialty Pharmacies Hospital Pharmacies Retail and Online Pharmacies Market Analysis by End User: Hospitals and Clinics Home Healthcare Market Analysis by Geography: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Class, Route of Administration, Distribution Channel, and End User Country-Level Breakdown: United States Canada Mexico Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Class, Route of Administration, Distribution Channel, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Class, Route of Administration, Distribution Channel, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Class, Route of Administration, Distribution Channel, and End User Country-Level Breakdown: Brazil Argentina Mexico Rest of Latin America Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Class, Route of Administration, Distribution Channel, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: GSK plc AstraZeneca plc NS Pharma/Nippon Shinyaku Roche/Genentech Novartis Sanofi Regeneron Pharmaceuticals Pfizer Sandoz Teva Pharmaceutical Industries Viatris AbbVie Inc. Amgen Inc. Johnson & Johnson UCB S.A. Competitive Landscape and Strategic Insights Benchmarking Based on Biologic Portfolio Strength, Steroid-Sparing Evidence, Regulatory Approvals, Reimbursement Access, Administration Convenience, Specialty Pharmacy Reach, and Regional Presence Pipeline Evaluation of Emerging Targeted Therapies and Oral Treatment Candidates Biologic Therapy Positioning and Sustained Remission Strategy Analysis Subcutaneous/Intramuscular Administration and Home Healthcare Competitiveness Specialty Pharmacy, Hospital Pharmacy, and Patient Access Strategy Analysis Analyst Commentary—Sustained Remission and Steroid Reduction Will Define Leadership Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Drug Class, Route of Administration, Distribution Channel, End User, and Geography (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading EGPA Treatment Vendors Treatment Pathway and Therapeutic Option Analysis Across Remission Induction, Remission Maintenance, Relapsing or Refractory EGPA, Severe and Organ-Threatening EGPA, Corticosteroid-Sparing Treatment, and Eosinophilic Respiratory Manifestation Control Technology and Treatment Adoption Trends Across Biologic Therapies, Steroids/Glucocorticoids, Immunosuppressants, Immune Globulins and Other Adjunctive Therapies, Subcutaneous/Intramuscular, Oral, and Intravenous Administration List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Drug Class, Route of Administration, Distribution Channel, and End User (2025 vs. 2032) Global Eosinophilic Granulomatosis with Polyangiitis Treatment Ecosystem and Value Chain Analysis